NASDAQ:AVIR
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. reported net income of −$158.3M in fiscal 2025. The diluted share count fell 3.3%.Summary generated from Atea Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−44.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change−3.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 351 | n/a | n/a | n/a | n/a |
| Operating income | 138 | −131 | −164 | −193 | −181 |
| Net income | 121 | −116 | −136 | −168 | −158 |
| Free cash flow | −87 | −123 | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jun 23, 2026 - 4Insider transaction report
Jun 23, 2026 - 8-KResults of a shareholder vote
Jun 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 12, 2026 - DEF 14AProxy statement
Apr 27, 2026